Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Revenue $0.2 million in Q3 2026, primarily from grants and service sales
- ➤Net loss $15.6 million, widening from $13.6 million year over year
- ➤Operating expenses $16.9 million, up 10% year over year
- ➤Cash, cash equivalents, and investments totaled $114.3 million at September 30
- ➤SEEDS consortium could provide up to $6 million in ARPA-H-funded research support
Expert Statements
Sujal Patel, CEO of Nautilus Biotechnology
“The third quarter marked an important step in demonstrating the power and scalability of Iterative Mapping on our Voyager platform.”
Sujal Patel, CEO of Nautilus Biotechnology
“Our seminal publication in Nature Methods highlights the unique biological insights that our technology can deliver.”
Sujal Patel, CEO of Nautilus Biotechnology
“In addition, our proteoform expansion initiative is on-track, with early oncology assay results that demonstrate the performance we established with Tau is repeatable across additional targets.”
Sujal Patel, CEO of Nautilus Biotechnology
“This repeatability is fundamental to our strategy of building a broad portfolio of proteoform assays, and the progress we are seeing reinforces our confidence in our technology, our development roadmap, and our planned instrument availability in the middle of 2027.”
SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 Business Highlights * Published a peer-reviewed paper in Nature Methods showing how Iterative Mapping reveals the proteoforms underlying biology and disease, with potential to yield new biomarkers and drug targets. * Shared first development data on oncology proteoform assays, including AKT1, at World HUPO 2026, showing a performance profile matching Tau and supporting platform extensibility. * Advanced the proteoform pipeline needed to deliver twenty assays planned through mid-2028. * Subsequent to quarter end, announced participation in SEEDS, a four-year, multi-center research consortium funded by ARPA-H, with Nautilus expecting to receive up to $6 million to deploy its Voyager Platform(TM) to measure proteoforms driving Alzheimer’s disease and cancer. “The third quarter marked an important step in demonstrating the power and scalability of Iterative Mapping on our Voyager platform,” said Sujal Patel, CEO of Nautilus Biotechnology. “Our seminal publication in Nature Methods highlights the unique biological insights that our technology can deliver. In addition, our proteoform expansion initiative is on-track, with early oncology assay results that demonstrate the performance we established with Tau is repeatable across additional targets. This repeatability is fundamental to our strategy of building a broad portfolio of proteoform assays, and the progress we are seeing reinforces our confidence in our technology, our development roadmap, and our planned instrument availability in the middle of 2027.”
Get started
Create a free account to read the full story.